ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : ÀÎÇ÷翣ÀÚ À¯Çüº°, Ä¡·áº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)
Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2024- 2032
»óǰÄÚµå : 1463146
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 118 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,827,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,198,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,569,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 13¾ï 8,621¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

°èÀý¼º ÀÎÇ÷翣ÀÚ À¯Çà, Àü¿°¼º È£Èí±â ÁúȯÀÇ À¯Çà, ÀÎÇ÷翣ÀÚ °ü·Ã ÇÕº´Áõ ¹ßº´ À§ÇèÀÌ ³ôÀº ȯÀÚ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ÀÎÇ÷翣ÀÚ È®»êÀ» ¾ïÁ¦Çϱâ À§ÇÑ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥°ú ÀÎÇ÷翣ÀÚ Á¶±â Áø´Ü ¹× Ä¡·áÀÇ Á߿伺¿¡ ´ëÇÑ Àνİú °°Àº Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹¸¦ µé¾î, 2023³â 9¿ù °Ç°­º¸È£¼¾ÅÍ(Centre for Health Protection)ÀÇ º¸°í¼­¿¡ µû¸£¸é, 2023³â 10¿ù¿¡ Á¤ºÎ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÌ ½ÃÀÛµÉ ¿¹Á¤À̸ç, ÀÌ¿¡ µû¶ó Á¤ºÎ´Â °èÀý¼º ÀÎÇ÷翣ÀÚ ¿¹¹æÁ¢Á¾À» ¹«·á·Î Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ºÐ¾ßÀÇ ¿¬±¸ °³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁö°í, ´õ ¸¹Àº Á¦¾àȸ»ç°¡ ¹ÙÀÌ·¯½ºÀÇ ¿©·¯ ´Ü°è¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ÀÎÇ÷翣ÀÚÀ» ´õ È¿À²ÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ´õ È¿°úÀûÀÎ Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿Á½ºÆ÷µå ´ëÇÐÀÌ 2023³â 10¿ù¿¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é, ¸Å³â ¾à 290,000¸í¿¡¼­ 650,000¸íÀÇ »ç¸ÁÀÚ¸¦ ¹ß»ý½ÃŰ´Â ÀÎÇ÷翣ÀÚ Ä¡·á¹ýÀ» ¿¬±¸Çϱâ À§ÇØ RECOVERY Æ®·¹ÀÏÀÌ È®´ëµÇ¾ú½À´Ï´Ù.

ÀÎÇ÷翣ÀÚ È®»ê¿¡ ´ëÀÀÇϱâ À§ÇØ º¸´Ù È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ç×¹ÙÀÌ·¯½ºÁ¦°¡ ÇÊ¿äÇÔ¿¡ µû¶ó °¢ Á¦¾à»çµéÀº Â÷¼¼´ë Ç×¹ÙÀÌ·¯½ºÁ¦¿Í °°Àº Çõ½ÅÀûÀÎ Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ Ç×¹ÙÀÌ·¯½ºÁ¦´Â È¿´ÉÀÌ Çâ»óµÇ°í, ¿©·¯ ÀÎÇ÷翣ÀÚ ±ÕÁÖ¿¡ ´ëÇØ ´õ ³ÐÀº Ȱ¼º ½ºÆåÆ®·³À» °¡Áö¸ç, ºÎÀÛ¿ëÀ» °¨¼Ò½ÃÄÑ ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ¼ö¿ä¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¸é¿ª ¹ÝÀÀÀ̳ª À¯ÀüÀû üÁú µî ȯÀÚ °³°³ÀÎÀÇ Æ¯¼º¿¡ µû¶ó ÀÎÇ÷翣ÀÚ Ä¡·á¸¦ Á¶Á¤ÇÏ´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á°¡ ¹ßÀüÇϰí ÀÖ´Â °Íµµ Àü ¼¼°è Á¦Ç° ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 7¿ù Àεµ °úÇÐ ¿¬±¸¼ÒÀÇ ¿¬±¸¿¡ µû¸£¸é, ÇÇÄݸ°»êÀº ÀÎÇ÷翣ÀÚÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áúº´À» À¯¹ßÇÏ´Â ¹ÙÀÌ·¯½º¸¦ Â÷´ÜÇÒ ¼ö ÀÖÀ¸¸ç, ÀϺΠ¹ÙÀÌ·¯½º¼º ÁúȯÀ» ÅðÄ¡ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù.

ÀÎÇ÷翣ÀÚÄ¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ÀÎÇ÷翣ÀÚ AÇü ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ºÎ¹®Àº ¹ßº´·ü Áõ°¡¿Í ÀûÀýÇÑ Åõ¾àÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ³ôÀº Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿À¼¿Å¸¹Ìºñ¸£ Àλ꿰Àº ¿©·¯ ±ÕÁÖ¿¡ ´ëÇÑ ³ôÀº È¿À²¼º°ú À¯È¿¼º µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ´ëºÎºÐÀÇ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

¿Â¶óÀÎ ¾à±¹ÀÇ ºÎ»óÀº ȯÀÚ¿¡°Ô Æí¸®ÇÔ°ú Á¢±Ù¼º µî ¿©·¯ °¡Áö ÀÌÁ¡À» °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â ÀÎÇ÷翣ÀÚÀÇ À¯Çà°ú »õ·Î¿î Á¦Á¦ °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡·Î ÀÎÇØ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ Ä¡·áÁ¦ ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå µ¶°¨ À¯Çüº° ¼¼°è ½ÃÀå

Á¦6Àå Ä¡·áº° ¼¼°è ½ÃÀå

Á¦7Àå À¯Åë ä³Îº° ¼¼°è ½ÃÀå

Á¦8Àå Áö¿ªº° ¼¼°è ½ÃÀå

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global influenza medications market size is expected to reach USD 1,386.21 million by 2032, according to a new study by Polaris Market Research. The report "Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The proliferation of seasonal flu, greater prevalence of contagious respiratory illness, and increasing patient population who are at higher risk of developing flu-related complications, are key factors driving the market growth. Growing number of government initiatives like vaccination programs for controlling the spread of influenza and awareness regarding the importance of early diagnosis and treatment of influenza, are further anticipated to propel market growth.

For instance, according a report by the Centre for Health Protection in September 2023, the Government Vaccination Programme was launched in October 2023 under which the government continued to provide seasonal influenza vaccination for free of cost.

Furthermore, growing research & development activities in the field of influenza medications and growing number of pharmaceutical companies implementing on the development of more effective antiviral drugs that can treat influenza more efficiently through targeting different stages of viral, are further boosting the market's growth. For instance, according to a report by the University of Oxford in October 2023, the RECOVERY trail has been expanded for investigating treatments for influenza that cause deaths of approx. 290,000 to 650,000 people each year.

As the need for effective and safer antiviral drugs to combat the spread of influenza, companies are introducing innovative antiviral drugs like next-generation antiviral drugs which offer enhanced efficacy, broader spectrum of activity against the several influenza strains, and reduced side effects, which is impacting the demand for influenza medications in a positive way.

Additionally, ongoing advances in personalized medicine tailoring to influenza treatment based on individual patient characteristics like immune response and genetic make-up, further escalating the product demand globally. For instance, according to a study done by the Indian Institute of Science in July 2023, it is reported that picolinic acid has the potential to block various disease-causing viruses including influenza and it also help to fight against several viral diseases.

Influenza Medications Market Report Highlights

Influenza A segment accounted for notable share, owing to rising incidences and awareness regarding the importance of proper medications

Oseltamivir phosphate segment held the majority share, that is attributed to its advantages including higher efficiency and effectiveness against several strains

Online pharmacies segment will grow at highest pace, emergence of online pharmacy platforms offering several benefits to patients like convenience and easy accessibility

North America dominated the market, on account of prevalence of influenza and rising investments in R&D activities to develop new formulations

The key market players include Bayer, Roche Diagnostics, Novartis, Sanofi, AstraZeneca, AbbVie, BioCryst Pharmaceuticals, and Mylan

Polaris Market Research has segmented the influenza medications market report based on influenza type, treatment, distribution channel, and region:

Influenza Medications, Influenza Type Outlook (Revenue - USD Million, 2023 - 2032)

Influenza Medications, Treatment Outlook (Revenue - USD Million, 2023 - 2032)

Influenza Medications, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)

Influenza Medications, Regional Outlook (Revenue - USD Million, 2023 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Influenza Medications Market Insights

5. Global Influenza Medications Market, by Influenza Type

6. Global Influenza Medications Market, by Treatment

7. Global Influenza Medications Market, by Distribution Channel

8. Global Influenza Medications Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â